Injectable Antiretroviral Drugs: Back to the Future
Abstract
:1. Introduction
2. Methods
3. Zidovudine (AZT)
3.1. Molecular Characteristics
3.2. Available Formulations
3.3. Recommended Doses
3.4. Place in Therapy
4. Enfuvirtide
4.1. Molecular Characteristics
4.2. Available Formulations
4.3. Recommended Doses
4.4. Place in Therapy
5. Rilpivirine (RPV; TMC278) Long Acting (RPV-LA)
5.1. Molecular Characteristics
5.2. Available Formulations
5.3. Recommended Doses
Clinical Trials with Cabotegravir (CAB-LA)
5.4. Place in Therapy
5.5. Place in Pre-Exposure Prophylaxis
6. Cabotegravir (CAB, GSK 1265744)
Molecular Characteristics and Available Formulations
7. Clinical Trials with RPV (RPV-LA)
7.1. Place in Therapy
7.2. Place in Pre-Exposure Prophylaxis
8. Ibalizumab
8.1. Molecular Characteristics
8.2. Available Formulations
8.3. Recommended Doses
8.4. Place in Therapy
9. GS-6207
9.1. Molecular Characteristics
9.2. Place in Therapy
10. Albuvirtide (ABT)
10.1. Molecular Characteristics
10.2. Place in Therapy
11. bNAbs
Place in Therapy
12. Discussion and Conclusions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Gottlieb, M.S.; Schroff, R.; Schanker, H.M.; Weisman, J.D.; Fan, P.T.; Wolf, R.A.; Saxon, A. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: Evidence of a new acquired cellular immunodeficiency. N. Engl. J. Med. 1981, 305, 1425–1431. [Google Scholar] [CrossRef]
- Unaids Data. 2020. Available online: https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf (accessed on 30 June 2020).
- Barré-Sinoussi, F.; Ross, A.L.; Delfraissy, J.-F. Past, present and future: 30 years of HIV research. Nat. Rev. Genet. 2013, 11, 877–883. [Google Scholar] [CrossRef] [PubMed]
- Zachariah, R.; Van Damme, W.; Arendt, V.; Schmit, J.C.; Harries, A.D. The HIV/AIDS epidemic in sub-Saharan Africa: Thinking ahead on programmatic tasks and related operational research. J. Int. AIDS Soc. 2011, 14, S7. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bain, L.E.; Nkoke, C.; Noubiap, J.J.N. UNAIDS 90-90-90 targets to end the AIDS epidemic by 2020 are not realistic: Comment on “Can the UNAIDS 90-90-90 target be achieved? A systematic analysis of national HIV treatment cascades”. BMJ Glob. Health 2017, 2, e000227. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Beccari, M.V.; Mogle, B.T.; Sidman, E.F.; Mastro, K.A.; Asiago-Reddy, E.; Kufel, W.D. Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 Infection. Antimicrob. Agents Chemother. 2019, 63. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Spreen, W.R.; Margolis, D.A.; Pottage, J.C. Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr. Opin. HIV AIDS 2013, 8, 565–571. [Google Scholar] [CrossRef] [PubMed]
- Riccardi, N.; Berruti, M.; Del Puente, F.; Taramasso, L.; Di Biagio, A. Ibalizumab and Fostemsavir in the Management of Heavily Pre-Treated HIV-infected Patients. Recent Patents Anti-Infect. Drug Discov. 2019, 13, 190–197. [Google Scholar] [CrossRef] [PubMed]
- Nyaku, A.N.; Kelly, S.G.; Taiwo, B.O. Long-Acting Antiretrovirals: Where Are We Now? Curr. HIV/AIDS Rep. 2017, 14, 63–71. [Google Scholar] [CrossRef] [PubMed]
- Darbyshire, J.; Foulkes, M.; Peto, R.; Duncan, W.; Babiker, A.; Collins, R.; Hughes, M.; Peto, T.E.; Walker, S.A.; Walker, A. Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults. Cochrane Database Syst. Rev. 2000, CD002038. [Google Scholar] [CrossRef]
- Bozzi, A.; D’Andrea, G.; Brisdelli, F. AZT: An old drug with new perspectives. Curr. Clin. Pharmacol. 2008, 3, 20–37. [Google Scholar] [CrossRef]
- Durand-Gasselin, L.; Pruvost, A.; Dehée, A.; Vaudre, G.; Tabone, M.-D.; Grassi, J.; Leverger, G.; Garbarg-Chenon, A.; Bénech, H.; Dollfus, C. High Levels of Zidovudine (AZT) and Its Intracellular Phosphate Metabolites in AZT- and AZT-Lamivudine-Treated Newborns of Human Immunodeficiency Virus-Infected Mothers. Antimicrob. Agents Chemother. 2008, 52, 2555–2563. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Available online: https://aidsinfo.nih.gov/guidelines/html/2/pediatric-arv/510/antiretroviral-management-of-newborns-with-perinatal-hiv-exposure-or-perinatal-hiv (accessed on 30 June 2020).
- Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States. Available online: https://aidsinfo.nih.gov/guidelines/html/3/perinatal/180/intrapartum-antiretroviral-therapy-prophylaxis (accessed on 30 June 2020).
- DeLory, T.; Papot, E.; Rioux, C.; Charpentier, C.; Auge-Courtoi, C.; Michard, F.; Peytavin, G.; Descamps, D.; Matheron, S.; Yazdanpanah, Y. Foscarnet, zidovudine and dolutegravir combination efficacy and tolerability for late stage HIV salvage therapy: A case-series experience. J. Med. Virol. 2015, 88, 1204–1210. [Google Scholar] [CrossRef] [PubMed]
- LaBonte, J.; Lebbos, J.; Kirkpatrick, P. Enfuvirtide. Nat. Rev. Drug Discov. 2003, 2, 345–346. [Google Scholar] [CrossRef] [PubMed]
- Reynes, J.; Arastéh, K.; Clotet, B.; Cohen, C.; Cooper, D.A.; Delfraissy, J.F.; Eron, J.J.; Henry, K.; Katlama, C.; Kuritzkes, D.R.; et al. TORO: Ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. AIDS Patient Care STDS 2007, 21, 533–543. [Google Scholar] [CrossRef] [PubMed]
- Taramasso, L.; Dentone, C.; Alessandrini, A.; Bruzzone, B.; Icardi, G.; Garraffo, R.; De Macina, I.; Viscoli, C.; Di Biagio, A. HIV/HCV Collaborative Liguria Group Successful antiretroviral therapy by using unusual antiretroviral combinations in heavily pre-treated patients: Two case reports. Int. J. STD AIDS 2014, 26, 831–834. [Google Scholar] [CrossRef]
- Viciana, P. Rilpivirine: The Key for Long-term Success. AIDS Rev. 2017, 19, 156–166. [Google Scholar] [CrossRef]
- Pozniak, A.; Morales-Ramirez, J.; Katabira, E.; Steyn, D.; Lupo, S.H.; Santoscoy, M.; Grinsztejn, B.; Ruxrungtham, K.; Rimsky, L.T.; Vanveggel, S.; et al. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: Week 96 results of a phase IIb randomized trial. AIDS 2010, 24, 55–65. [Google Scholar] [CrossRef]
- Taramasso, L.; Di Biagio, A.; Riccardi, N.; Briano, F.; Di Filippo, E.; Comi, L.; Mora, S.; Giacomini, M.; Gori, A.; Maggiolo, F. Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafena-mide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia. PLoS ONE 2019, 11, e0223181. [Google Scholar]
- van’t Klooster, G.; Hoeben, E.; Borghys, H.; Looszova, A.; Bouche, M.P.; van Velsen, F.; Baert, L. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob. Agents Chemother. 2010, 54, 2042–2050. [Google Scholar] [CrossRef] [Green Version]
- Verloes, R.; Deleu, S.; Niemeijer, N.; Crauwels, H.; Meyvisch, P.; Williams, P. Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers: RPV long-acting formulation: Safety and PK. HIV Med. 2015, 16, 477–484. [Google Scholar] [CrossRef]
- Margolis, D.A.; Gonzalez-Garcia, J.; Stellbrink, H.J.; Eron, J.J.; Yazdanpanah, Y.; Podzamczer, D.; Lutz, T.; Angel, J.B.; Richmond, G.J.; Clotet, B.; et al. Safety, Efficacy and Durability of Long-acting Cabotegravir (CAB) and Rilpivirine (RPV) as Two-Drug IM Maintenance Therapy for HIV-1 Infection: LATTE-2 Week 160 Results Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet 2017, 390, 1499–1510. [Google Scholar] [PubMed]
- Orkin, C.; Arasteh, K.; Hernández-Mora, M.G.; Pokrovsky, V.; Overton, E.T.; Girard, P.-M.; Oka, S.; Walmsley, S.; Bettacchi, C.; Brinson, C.; et al. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection. N. Engl. J. Med. 2020, 382, 1124–1135. [Google Scholar] [CrossRef]
- Swindells, S.; Andrade-Villanueva, J.-F.; Richmond, G.J.; Rizzardini, G.; Baumgarten, A.; Masiá, M.; Latiff, G.; Pokrovsky, V.; Bredeek, F.; Smith, G.; et al. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression. N. Engl. J. Med. 2020, 382, 1112–1123. [Google Scholar] [CrossRef]
- Bekker, L.-G.; Li, S.; Pathak, S.; Tolley, E.; Marzinke, M.; Justman, J.; Mgodi, N.; Chirenje, M.; Swaminathan, S.; Adeyeye, A.; et al. Safety and tolerability of injectable Rilpivirine LA in HPTN 076: A phase 2 HIV pre-exposure prophylaxis study in women. EClinicalMedicine 2020, 21, 100303. [Google Scholar] [CrossRef] [PubMed]
- Whitfield, T.; Torkington, A.; Van Halsema, C. Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: Evidence to date. HIV/AIDS Res. Palliat. Care 2016, 8, 157–164. [Google Scholar] [CrossRef] [Green Version]
- Kirby, T. Cabotegravir, a new option for PrEP. Lancet Infect. Dis. 2020, 20, 781. [Google Scholar] [CrossRef]
- Song, R.; Franco, D.; Kao, C.-Y.; Yu, F.; Huang, Y.; Ho, D.D. Epitope Mapping of Ibalizumab, a Humanized Anti-CD4 Monoclonal Antibody with Anti-HIV-1 Activity in Infected Patients. J. Virol. 2010, 84, 6935–6942. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Emu, B.; Fessel, J.; Schrader, S.; Kumar, P.; Richmond, G.; Win, S.; Weinheimer, S.; Marsolais, C.; Lewis, S. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1. N. Engl. J. Med. 2018, 379, 645–654. [Google Scholar] [CrossRef]
- Markham, A. Correction to: Ibalizumab: First Global Approval. Drugs 2018, 78, 859. [Google Scholar] [CrossRef] [Green Version]
- Yant, S.R.; Mulato, A.; Stepan, G.; Villasenor, A.G.; Jin, D.; Margot, N.A.; Ahmadyar, S.; Ram, R.R.; Somoza, J.R.; Singer, E.; et al. GS-6207, a Potent and Selective First-in-Class Long-Acting HIV-1 Capsid Inhibitor. In Proceedings of the Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA, 4–7 March 2019. Abstract 480. [Google Scholar]
- Daar, E.; McDonald, C.; Crofoot, G.; Ruane, P.; Sinclair, G.; De Jesus, E.; Berhe, M.; Ramgopal, M.; Patel, H.; Liu, Y.P.; et al. Dose-Response Relationship of Subcutaneous Long-Acting HIV Capsid Inhibitor GS-6207. In Proceedings of the Retro Conference on HIV and Opportunistic Infections, Boston, MA, USA, 8–11 March 2020. Poster 3691. [Google Scholar]
- Chong, H.; Yao, X.; Zhang, C.; Cai, L.; Cui, S.; Wang, Y.; He, Y. Biophysical Property and Broad Anti-HIV Activity of Albuvirtide, a 3-Maleimimidopropionic Acid-Modified Peptide Fusion Inhibitor. PLoS ONE 2012, 7, e32599. [Google Scholar] [CrossRef] [Green Version]
- Wu, H.; Yao, C.; Lu, R.J.; Zhang, T.; Wang, M.X.; Zhao, H.X.; Peng, H.Y.; Xie, Y.; Min, W.J.; Jiang, H.; et al. Albuvirtide, the first long-acting HIV-1 fusion inhibitor, suppressed viral replication in HIV-infected adults. In Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, USA, 9–12 September 2012. Paper H-554. [Google Scholar]
- Zhang, H.-W.; Jin, R.; Yao, C.; Zhang, T.; Wang, M.-X.; Xia, W.; Peng, H.; Wang, X.; Lu, R.J.; Wang, C.; et al. Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients. AIDS Res. Ther. 2016, 13, 8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Su, B.; Yao, C.; Zhao, Q.X.; Cai, W.P.; Wang, M.; Lu, H.Z.; Chen, Y.Y.; Liu, L.; Wang, H.; He, Y.; et al. Efficacy and safety of the long-acting fusion inhibitor al-buvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: Interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study. Chin. Med. J. (England) 2020, 133, 2919–2927. [Google Scholar] [CrossRef] [PubMed]
- Liu, Y.; Cao, W.; Sun, M.; Cao, W. Broadly neutralizing antibodies for HIV-1: Efficacies, challenges and opportunities. Emerg. Microbes Infect. 2020, 9, 194–206. [Google Scholar] [CrossRef]
- Ghosn, J.; Pellegrin, I.; Goujard, C.; Deveau, C.; Viard, J.-P.; Galimand, J.; Harzic, M.; Tamalet, C.; Meyer, L.; Rouzioux, C.; et al. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 2006, 20, 159–170. [Google Scholar] [CrossRef] [PubMed]
- Chiodini, J. HIV drug interaction resources from the University of Liverpool. Travel Med. Infect. Dis. 2016, 14, 292–293. [Google Scholar] [CrossRef]
- Prinapori, R.; Giannini, B.; Riccardi, N.; Bovis, F.; Giacomini, M.; Setti, M.; Viscoli, C.; Artioli, S.; Di Biagio, A. Predictors of retention in care in HIV-infected patients in a large hospital cohort in Italy. Epidemiol. Infect. 2018, 146, 606–611. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Capetti, A.F.; De Socio, G.V.; Cossu, M.V.; Sterrantino, G.; Cenderello, G.; Cattelan, A.; Baldin, G.; Soria, A.; Riccardi, N.; Niero, F.P.; et al. Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects. HIV Clin. Trials 2018, 19, 242–248. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Berruti, M.; Riccardi, N.; Canetti, D.; Lo Caputo, S.; Taramasso, L.; Di Biagio, A. Injectable Antiretroviral Drugs: Back to the Future. Viruses 2021, 13, 228. https://doi.org/10.3390/v13020228
Berruti M, Riccardi N, Canetti D, Lo Caputo S, Taramasso L, Di Biagio A. Injectable Antiretroviral Drugs: Back to the Future. Viruses. 2021; 13(2):228. https://doi.org/10.3390/v13020228
Chicago/Turabian StyleBerruti, Marco, Niccolò Riccardi, Diana Canetti, Sergio Lo Caputo, Lucia Taramasso, and Antonio Di Biagio. 2021. "Injectable Antiretroviral Drugs: Back to the Future" Viruses 13, no. 2: 228. https://doi.org/10.3390/v13020228